NCT05898178

Brief Summary

The purpose of this study is to investigate the development of human embryos in vitro under two different oxygen concentrations; a static 5% during all five days of culture or under an oxygen gradient, starting with 8% from day-0 to day-3, continuing with 5% on day-3 and following with 2% of oxygen from the end of day-3 to day-5.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
44

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jan 2022

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2022

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2023

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

April 26, 2023

Completed
2 months until next milestone

First Posted

Study publicly available on registry

June 12, 2023

Completed
2 years until next milestone

Results Posted

Study results publicly available

June 8, 2025

Completed
Last Updated

June 8, 2025

Status Verified

June 1, 2025

Enrollment Period

1 year

First QC Date

April 26, 2023

Results QC Date

April 24, 2025

Last Update Submit

June 5, 2025

Conditions

Keywords

Embryo culture, reduced oxygen, time-lapse, blastocyst

Outcome Measures

Primary Outcomes (1)

  • Proportion of Inseminated Oocytes Developed to the Morphologically Optimal Blastocysts on Day 5

    The primary outcome measure will be the proportion of oocytes that will develop to the morphologically optimal day-5 blastocysts, scored 4-5AA according to Gardner criteria. According to the scoring system of Gardner, blastocyst morphology parameters such as the degree of blastocoel expansion (1-5), the morphological appearance of the inner cell mass (ICM) (A, B, C) and the cohesiveness of trophectoderm (TE) (A, B, C) will be measured.

    Embryos will be annotated on day 5 post insemination (at 8:00 am).

Secondary Outcomes (4)

  • Measured Times From Insemination to Different Embryonic Stages Reached

    Morphokinetic timings were recorded continuously (every 5 minutes) throughout embryo culture, up to 124 hours (Day 5) post-insemination.

  • Blastocyst and Inner Cell Mass (ICM) Surface Area Measurement on Day 5

    Fix time (116 hours) post insemination

  • Number of Trophectoderm Cells on Day 5

    Fix time (116 hours) post insemination.

  • Incidence of Atypical Embryo Cleavages

    Continuously (a picture will be taken every 5 minutes) during 5 days of embryo culture.

Study Arms (2)

8-5-2% oxygen gradient concentration in the incubator

EXPERIMENTAL

A physiological oxygen gradient concentration in the incubator (8-5-2% O2).

Other: Experimental intervention: 8-5-2% oxygen gradient concentration in the incubator

Control (no intervention)

NO INTERVENTION

Arbitrary cultivation conditions (static 5% 02).

Interventions

After oocyte retrieval and insemination, half of a given patient's embryos will be randomly allocated in an incubator set at a gradient of oxygen tension (8-5-2%). The embryos will remain in the incubator until their developmental assessments on day 5.

8-5-2% oxygen gradient concentration in the incubator

Eligibility Criteria

Age18 Years - 35 Years
Sexfemale(Gender-based eligibility)
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Age of women between 18 and 35 years.
  • Body mass index (BMI) between 18 and 30 kg/m².
  • Only patients with ICSI procedure (male factor of infertility, excluding azoospermia) and blastocyst culture.
  • Patients from first and second ICSI cycle attempt.
  • Gonadotropin hormone-releasing hormone (GnRH) antagonist cycles.

You may not qualify if:

  • Presence of endometriosis.
  • Previous clinical intervention on ovaries.
  • Connected endocrine or metabolic diseases.
  • Presence of polycystic ovary syndrome.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Medical Centre Maribor

Maribor, 2000, Slovenia

Location

Results Point of Contact

Title
Borut Kovačič
Organization
Maribor University Medical Centr

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
INVESTIGATOR
Masking Details
The cohort of oocyte-cumulus complexes will be divided into either the study or control group by simple randomization. All embryologists involved in the study will be blinded during embryo assessment, measurement, and selection for embryo transfer or vitrification. A code system will be used on the Petri dishes to ensure the embryologists are blinded.
Purpose
OTHER
Intervention Model
PARALLEL
Model Details: 496 sibling oocytes will be randomly allocated for culture either at low oxygen tension (5% O2) (n = 248 oocytes) or a more physiological oxygen gradient (8-5-2% O2) (n = 248 oocytes) for the next 5 days. Immediately after allocation, the oocytes will be inseminated through Intracytoplasmic Sperm Injection (ICSI). The sibling oocytes will always be injected by the same embryologist. Under standard (5%) oxygen concentration, which is currently being used in the cultivating incubators, approximately 15% of all embryos manage to reach a morphological optimal blastocyst, in a patient group younger than 35 years (see Inclusion Criteria). According to the hypothesis that cultivating embryos under a more physiological atmosphere (gradient from 8% to 2%) improves the blastulation rate of embryos to 25%, a sample size of 496 Injected oocytes (248 in each arm), will be needed. Whereby a statistical strength of 80% and α = 0.05 is considered (calculated using power analysis).
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Prof. Borut Kovačič, PhD

Study Record Dates

First Submitted

April 26, 2023

First Posted

June 12, 2023

Study Start

January 1, 2022

Primary Completion

January 1, 2023

Study Completion

January 1, 2023

Last Updated

June 8, 2025

Results First Posted

June 8, 2025

Record last verified: 2025-06

Locations